Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Modelling variable proton relative biological effectiveness for treatment planning.

McNamara A, Willers H, Paganetti H.

Br J Radiol. 2019 Nov 18:20190334. doi: 10.1259/bjr.20190334. [Epub ahead of print]

PMID:
31738081
2.

Toward a New Framework for Clinical Radiation Biology.

Willers H, Keane FK, Kamran SC.

Hematol Oncol Clin North Am. 2019 Dec;33(6):929-945. doi: 10.1016/j.hoc.2019.07.001. Epub 2019 Sep 17. Review.

PMID:
31668212
3.

Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.

Gurtner K, Kryzmien Z, Koi L, Wang M, Benes CH, Hering S, Willers H, Baumann M, Krause M.

Int J Cancer. 2019 Jul 29. doi: 10.1002/ijc.32598. [Epub ahead of print]

PMID:
31359406
4.

Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.

Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, Van Seventer EE, Tracy A, Wo JY, Carter SL, Willers H, Corcoran RB, Hong TS, Van Allen EM.

Clin Cancer Res. 2019 Sep 15;25(18):5561-5571. doi: 10.1158/1078-0432.CCR-19-0908. Epub 2019 Jun 28.

PMID:
31253631
5.

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.

Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H.

Cell Rep. 2019 Jun 18;27(12):3422-3432.e4. doi: 10.1016/j.celrep.2019.05.058.

6.

Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer.

Sebastian N, Wu T, Driscoll E, Willers H, Kelly S, Musunuru HB, Mo X, Tan Y, Bazan J, Haglund K, Xu-Welliver M, Baschnagel AM, Ju A, Keane F, Williams TM.

Radiother Oncol. 2019 Nov;140:26-33. doi: 10.1016/j.radonc.2019.05.014. Epub 2019 Jun 5.

PMID:
31176206
7.

Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Grassberger C, McClatchy D 3rd, Geng C, Kamran SC, Fintelmann F, Maruvka YE, Piotrowska Z, Willers H, Sequist LV, Hata AN, Paganetti H.

Cancer Res. 2019 Jul 15;79(14):3776-3788. doi: 10.1158/0008-5472.CAN-18-3652. Epub 2019 May 21.

PMID:
31113818
8.

Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons.

Li Y, Dykstra M, Best TD, Pursley J, Chopra N, Keane FK, Khandekar MJ, Sharp GC, Paganetti H, Willers H, Fintelmann FJ, Grassberger C.

Radiother Oncol. 2019 Jul;136:169-175. doi: 10.1016/j.radonc.2019.04.004. Epub 2019 Apr 20.

PMID:
31015121
9.

Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.

Sebastian N, Wu T, Bazan J, Driscoll E, Willers H, Yegya-Raman N, Bond L, Dwivedi A, Mo X, Tan Y, Xu-Welliver M, Haglund K, Jabbour SK, Keane FK, Williams TM.

Radiother Oncol. 2019 May;134:151-157. doi: 10.1016/j.radonc.2019.01.032. Epub 2019 Feb 15.

PMID:
31005209
10.

Report of the AAPM TG-256 on the relative biological effectiveness of proton beams in radiation therapy.

Paganetti H, Blakely E, Carabe-Fernandez A, Carlson DJ, Das IJ, Dong L, Grosshans D, Held KD, Mohan R, Moiseenko V, Niemierko A, Stewart RD, Willers H.

Med Phys. 2019 Mar;46(3):e53-e78. doi: 10.1002/mp.13390. Epub 2019 Feb 14.

PMID:
30661238
11.

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.

Dinkelborg PH, Wang M, Gheorghiu L, Gurski JM, Hong TS, Benes CH, Juric D, Jimenez RB, Borgmann K, Willers H.

Breast Cancer Res Treat. 2019 Apr;174(3):605-613. doi: 10.1007/s10549-018-05079-7. Epub 2019 Jan 3.

PMID:
30607635
12.

TP53 mutation status: emerging biomarker for precision radiation medicine?

Willers H, Wang M, Benes CH.

Oncoscience. 2018 Aug 28;5(9-10):258-259. doi: 10.18632/oncoscience.468. eCollection 2018 Sep. No abstract available.

13.

Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios.

Aktar R, Dietrich A, Tillner F, Kotb S, Löck S, Willers H, Baumann M, Krause M, Bütof R.

Br J Radiol. 2019 Mar;92(1095):20180539. doi: 10.1259/bjr.20180539. Epub 2018 Oct 11.

PMID:
30215546
14.

Toward A variable RBE for proton beam therapy.

Willers H, Allen A, Grosshans D, McMahon SJ, von Neubeck C, Wiese C, Vikram B.

Radiother Oncol. 2018 Jul;128(1):68-75. doi: 10.1016/j.radonc.2018.05.019. Epub 2018 Jun 14. Review.

15.

Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.

Bristow RG, Alexander B, Baumann M, Bratman SV, Brown JM, Camphausen K, Choyke P, Citrin D, Contessa JN, Dicker A, Kirsch DG, Krause M, Le QT, Milosevic M, Morris ZS, Sarkaria JN, Sondel PM, Tran PT, Wilson GD, Willers H, Wong RKS, Harari PM.

Lancet Oncol. 2018 May;19(5):e240-e251. doi: 10.1016/S1470-2045(18)30096-2. Review.

PMID:
29726389
16.

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.

Khandekar MJ, Piotrowska Z, Willers H, Sequist LV.

Oncologist. 2018 Sep;23(9):1054-1062. doi: 10.1634/theoncologist.2017-0557. Epub 2018 Apr 27. Review.

17.

PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.

Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H.

Oncogene. 2018 May;37(21):2793-2805. doi: 10.1038/s41388-018-0130-6. Epub 2018 Mar 7.

18.

The Future of Radiobiology.

Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ.

J Natl Cancer Inst. 2018 Apr 1;110(4):329-340. doi: 10.1093/jnci/djx231.

19.

Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference.

Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):274-284. doi: 10.1016/j.ijrobp.2017.05.044. Epub 2017 Jun 9.

PMID:
28964588
20.

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.

PMID:
28954285
21.

Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

Wang M, Han J, Marcar L, Black J, Liu Q, Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, Hong TS, Gurtner K, Krause M, Baumann M, Kang JX, Whetstine JR, Willers H.

Cancer Res. 2017 Apr 15;77(8):2018-2028. doi: 10.1158/0008-5472.CAN-16-0808. Epub 2017 Feb 15.

22.

Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer.

Verma V, Simone CB 2nd, Allen PK, Gajjar SR, Shah C, Zhen W, Harkenrider MM, Hallemeier CL, Jabbour SK, Matthiesen CL, Braunstein SE, Lee P, Dilling TJ, Allen BG, Nichols EM, Attia A, Zeng J, Biswas T, Paximadis P, Wang F, Walker JM, Stahl JM, Daly ME, Decker RH, Hales RK, Willers H, Videtic GM, Mehta MP, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):362-371. doi: 10.1016/j.ijrobp.2016.10.041. Epub 2016 Nov 2.

PMID:
28011047
23.

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H.

Oncologist. 2016 Aug;21(8):964-73. doi: 10.1634/theoncologist.2015-0508. Epub 2016 Jun 27. Review.

24.

Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.

Coleman CN, Higgins GS, Brown JM, Baumann M, Kirsch DG, Willers H, Prasanna PG, Dewhirst MW, Bernhard EJ, Ahmed MM.

Clin Cancer Res. 2016 Jul 1;22(13):3138-47. doi: 10.1158/1078-0432.CCR-16-0069. Epub 2016 May 6. Review.

25.

Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation.

Liu Q, Underwood TS, Kung J, Wang M, Lu HM, Paganetti H, Held KD, Hong TS, Efstathiou JA, Willers H.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):78-85. doi: 10.1016/j.ijrobp.2016.01.046. Epub 2016 Feb 1.

26.

Effects of Charged Particles on Human Tumor Cells.

Held KD, Kawamura H, Kaminuma T, Paz AE, Yoshida Y, Liu Q, Willers H, Takahashi A.

Front Oncol. 2016 Feb 12;6:23. doi: 10.3389/fonc.2016.00023. eCollection 2016. Review.

27.

Multi-criteria optimization achieves superior normal tissue sparing in a planning study of intensity-modulated radiation therapy for RTOG 1308-eligible non-small cell lung cancer patients.

Kamran SC, Mueller BS, Paetzold P, Dunlap J, Niemierko A, Bortfeld T, Willers H, Craft D.

Radiother Oncol. 2016 Mar;118(3):515-20. doi: 10.1016/j.radonc.2015.12.028. Epub 2016 Jan 28.

PMID:
26830694
28.

DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

Willers H, Gheorghiu L, Liu Q, Efstathiou JA, Wirth LJ, Krause M, von Neubeck C.

Semin Radiat Oncol. 2015 Oct;25(4):237-50. doi: 10.1016/j.semradonc.2015.05.007. Epub 2015 May 14. Review.

29.

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy.

Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, Sequist LV.

J Thorac Oncol. 2015 Nov;10(11):1601-7. doi: 10.1097/JTO.0000000000000648.

30.

A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies.

Al-Halabi H, Paetzold P, Sharp GC, Olsen C, Willers H.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):803-10. doi: 10.1016/j.ijrobp.2015.03.018. Epub 2015 Mar 25.

PMID:
26104934
31.

Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation.

Liu Q, Ghosh P, Magpayo N, Testa M, Tang S, Gheorghiu L, Biggs P, Paganetti H, Efstathiou JA, Lu HM, Held KD, Willers H.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1081-9. doi: 10.1016/j.ijrobp.2014.12.046.

PMID:
25832698
32.

ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer.

Willers H, Stinchcombe TE, Barriger RB, Chetty IJ, Ginsburg ME, Kestin LL, Kumar S, Loo BW Jr, Movsas B, Rimner A, Rosenzweig KE, Videtic GM, Chang JY; Expert Panel on Radiation Oncology-Lung:.

Am J Clin Oncol. 2015 Apr;38(2):197-205. doi: 10.1097/COC.0000000000000154.

PMID:
25803563
33.

Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Liu Q, Wang M, Kern AM, Khaled S, Han J, Yeap BY, Hong TS, Settleman J, Benes CH, Held KD, Efstathiou JA, Willers H.

Mol Cancer Res. 2015 Apr;13(4):713-20. doi: 10.1158/1541-7786.MCR-14-0570. Epub 2015 Feb 9.

34.

Towards an integrated understanding of epidermal growth factor receptor biology for radiation therapy: integrins enter.

Willers H, Hong TS.

J Natl Cancer Inst. 2015 Feb 5;107(2). pii: dju440. doi: 10.1093/jnci/dju440. Print 2015 Feb. No abstract available.

PMID:
25663686
35.

53BP1 promotes microhomology-mediated end-joining in G1-phase cells.

Xiong X, Du Z, Wang Y, Feng Z, Fan P, Yan C, Willers H, Zhang J.

Nucleic Acids Res. 2015 Feb 18;43(3):1659-70. doi: 10.1093/nar/gku1406. Epub 2015 Jan 13.

36.

ACR appropriateness Criteria® early-stage non-small-cell lung cancer.

Videtic GM, Chang JY, Chetty IJ, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Loo BW Jr, Movsas B, Stinchcombe TE, Willers H, Rosenzweig KE; Expert Panel on Radiation OncologyLung.

Am J Clin Oncol. 2014 Apr;37(2):201-7. doi: 10.1097/COC.0000000000000013. Review.

PMID:
25180631
37.

ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent.

Chang JY, Kestin LL, Barriger RB, Chetty IJ, Ginsburg ME, Kumar S, Loo BW Jr, Movsas B, Rimner A, Rosenzweig KE, Stinchcombe TE, Videtic GM, Willers H.

Oncology (Williston Park). 2014 Aug 15;28(8):706-10, 712, 714 passim. Review.

38.

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.

Mak KS, Gainor JF, Niemierko A, Oh KS, Willers H, Choi NC, Loeffler JS, Sequist LV, Shaw AT, Shih HA.

Neuro Oncol. 2015 Feb;17(2):296-302. doi: 10.1093/neuonc/nou146. Epub 2014 Jul 22.

39.

EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.

Wang M, Kern AM, Hülskötter M, Greninger P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, Efstathiou JA, Settleman J, Willers H.

Cancer Res. 2014 May 15;74(10):2825-34. doi: 10.1158/0008-5472.CAN-13-3157. Epub 2014 Mar 19.

40.

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

Pfäffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H.

Cancer Res. 2013 Oct 15;73(20):6254-63. doi: 10.1158/0008-5472.CAN-13-0044. Epub 2013 Aug 21.

41.

Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.

Seco J, Gu G, Marcelos T, Kooy H, Willers H.

Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):188-94. doi: 10.1016/j.ijrobp.2013.04.048.

PMID:
23920395
42.

ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.

Rosenzweig KE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Langer CJ, Movsas B, Videtic GM, Willers H.

J Am Coll Radiol. 2013 Sep;10(9):654-64. doi: 10.1016/j.jacr.2013.05.031. Epub 2013 Jul 25.

PMID:
23890874
43.

Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer.

Willers H, Azzoli CG, Santivasi WL, Xia F.

Cancer J. 2013 May-Jun;19(3):200-7. doi: 10.1097/PPO.0b013e318292e4e3. Review.

44.

ACR Appropriateness Criteria® radiation therapy for small-cell lung cancer.

Kong FM, Lally BE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Langer CJ, Movsas B, Videtic GM, Willers H, Rosenzweig KE; Expert Panel on Radiation Oncology-Lung.

Am J Clin Oncol. 2013 Apr;36(2):206-13. doi: 10.1097/COC.0b013e31827e5523. Review.

PMID:
23511336
45.

Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancer.

Grassberger C, Dowdell S, Lomax A, Sharp G, Shackleford J, Choi N, Willers H, Paganetti H.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):380-6. doi: 10.1016/j.ijrobp.2013.01.024. Epub 2013 Feb 22.

46.

Multidisciplinary management of small cell lung cancer.

Goldberg SB, Willers H, Heist RS.

Surg Oncol Clin N Am. 2013 Apr;22(2):329-43. doi: 10.1016/j.soc.2012.12.002. Epub 2013 Jan 9. Review.

PMID:
23453338
47.

Detection of impaired homologous recombination repair in NSCLC cells and tissues.

Birkelbach M, Ferraiolo N, Gheorghiu L, Pfäffle HN, Daly B, Ebright MI, Spencer C, O'Hara C, Whetstine JR, Benes CH, Sequist LV, Zou L, Dahm-Daphi J, Kachnic LA, Willers H.

J Thorac Oncol. 2013 Mar;8(3):279-86. doi: 10.1097/JTO.0b013e31827ecf83.

48.

Proton SBRT for medically inoperable stage I NSCLC.

Westover KD, Seco J, Adams JA, Lanuti M, Choi NC, Engelsman M, Willers H.

J Thorac Oncol. 2012 Jun;7(6):1021-5. doi: 10.1097/JTO.0b013e31824de0bf.

49.

Radiofrequency ablation for stage I non-small cell lung cancer: management of locoregional recurrence.

Lanuti M, Sharma A, Willers H, Digumarthy SR, Mathisen DJ, Shepard JA.

Ann Thorac Surg. 2012 Mar;93(3):921-7; discussion 927-88. doi: 10.1016/j.athoracsur.2011.11.043. Epub 2012 Jan 31.

PMID:
22296982
50.

A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy.

Mak RH, Alexander BM, Asomaning K, Heist RS, Liu CY, Su L, Zhai R, Ancukiewicz M, Napolitano B, Niemierko A, Willers H, Choi NC, Christiani DC.

Cancer. 2012 Jul 15;118(14):3654-65. doi: 10.1002/cncr.26667. Epub 2011 Dec 5.

Supplemental Content

Loading ...
Support Center